BioAtla, Inc.
BCAB · Biological Products, (No Diagnostic Substances) · 32.3M shares · +55%/yr ↑ dilution · EDGAR filings ↗
Grade
F34Clinical/early-stage biotech — near-insolvent.
Strengths
- Liquidity — current ratio 0.37 (10th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Weak liquidityCurrent ratio 0.37 (<1)
- Chronic dilutionShare count +55%/yr over 4y (dilution, book value/share -103%)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
164.7%
Return on assets
-431.1%
Current ratio
0.4×
EBITDA
-$59M
Tangible book value
-$36M
Cash & investments
$7M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-31 | Vasquez Christian | Tax withheld | 82 | $3.93 |
| 2026-05-31 | SHORT JAY M PHD | Tax withheld | 259 | $3.93 |
| 2026-05-31 | Sievers Eric | Tax withheld | 134 | $3.93 |
| 2026-03-12 | SHORT JAY M PHD | Tax withheld | 639 | $0.17 |
| 2026-03-11 | SHORT JAY M PHD | Grant | 430K | — |
| 2026-03-11 | Sievers Eric | Tax withheld | 360 | $0.17 |
| 2026-03-11 | Vasquez Christian | Tax withheld | 175 | $0.17 |
| 2026-03-10 | Vasquez Christian | Grant | 240K | — |
| 2026-03-10 | Sievers Eric | Grant | 240K | — |
| 2026-02-28 | SHORT JAY M PHD | Tax withheld | 7.7K | $0.25 |
| 2026-02-28 | Vasquez Christian | Tax withheld | 1.8K | $0.25 |
| 2026-02-28 | WALDRON RICHARD A | Tax withheld | 2.7K | $0.25 |
| 2026-02-28 | Sievers Eric | Tax withheld | 3.1K | $0.25 |
| 2025-11-30 | WALDRON RICHARD A | Tax withheld | 2.4K | $0.90 |
| 2025-11-30 | Sievers Eric | Tax withheld | 2.7K | $0.90 |
| 2025-11-30 | SHORT JAY M PHD | Tax withheld | 6.3K | $0.90 |
| 2025-11-30 | Vasquez Christian | Tax withheld | 1.6K | $0.90 |
| 2025-08-31 | Sievers Eric | Tax withheld | 2.7K | $0.46 |
| 2025-08-31 | SHORT JAY M PHD | Tax withheld | 6.3K | $0.46 |
| 2025-08-31 | Vasquez Christian | Tax withheld | 1.6K | $0.46 |
| 2025-08-31 | WALDRON RICHARD A | Tax withheld | 2.4K | $0.46 |
| 2025-06-18 | Williams Eddie | Grant | 24K | — |
| 2025-06-18 | STEINMAN LAWRENCE | Grant | 24K | — |
| 2025-06-18 | GRAY MARY ANN | Grant | 24K | — |
| 2025-06-18 | Moran Susan | Grant | 24K | — |
| 2025-06-18 | MCBRINN SYLVIA | Grant | 24K | — |
| 2025-06-18 | Smith Scott Andrew | Grant | 24K | — |
| 2025-05-31 | Vasquez Christian | Tax withheld | 1.6K | $0.41 |
| 2025-05-31 | SHORT JAY M PHD | Tax withheld | 6.3K | $0.41 |
| 2025-05-31 | WALDRON RICHARD A | Tax withheld | 2.4K | $0.41 |
| 2025-05-31 | Sievers Eric | Tax withheld | 2.7K | $0.41 |
| 2025-03-12 | SHORT JAY M PHD | Grant | 431K | — |
| 2025-03-11 | Vasquez Christian | Grant | 85K | — |
| 2025-03-11 | WALDRON RICHARD A | Grant | 100K | — |
| 2025-03-11 | Sievers Eric | Grant | 175K | — |
| 2025-02-16 | SHORT JAY M PHD | Tax withheld | 31K | $0.46 |
| 2025-02-15 | Sievers Eric | Tax withheld | 13K | $0.46 |
| 2025-02-15 | WALDRON RICHARD A | Tax withheld | 11K | $0.46 |
| 2025-02-15 | Vasquez Christian | Tax withheld | 7.2K | $0.46 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05808634 ↗ | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. Advanced Adenocarcinoma | PHASE1 | Recruiting | 2028-09-15 |
| NCT05180799 ↗ | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors NSCLC, Melanoma | PHASE1/PHASE2 | Active Not Recruiting | 2025-03-19 |
| NCT05271604 ↗ | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | PHASE2 | Completed | 2025-09-22 |
| NCT04681131 ↗ | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC Non-Small-Cell Lung Cancer | PHASE2 | Completed | 2025-07-09 |
| NCT03425279 ↗ | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | PHASE1/PHASE2 | Completed | 2025-01-08 |
| NCT03504488 ↗ | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) Non Small Cell Lung Cancer, Triple Negative Breast Cancer | PHASE1/PHASE2 | Completed | 2024-12-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-04-02 | OtherExhibits | filing ↗ |
| 2026-03-31 | ResultsReg FD | filing ↗ |
| 2026-03-23 | Exec/director changeShareholder vote | filing ↗ |
| 2026-03-02 | Results2.05Exec/director changeReg FDOtherExhibits | filing ↗ |
| 2026-02-09 | Other | filing ↗ |
| 2026-02-06 | Delisting noticeReg FD | filing ↗ |
| 2026-01-30 | 5.03Shareholder voteReg FDOtherExhibits | filing ↗ |
| 2026-01-12 | 3.025.03Shareholder voteOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-05-15 | 2026-03-31 | 0001193125-26-226631 ↗ |
| 10-K/A | 2026-04-29 | 2025-12-31 | 0001193125-26-191493 ↗ |
| 8-K | 2026-04-02 | 2026-04-02 | 0001193125-26-140053 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001193125-26-134499 ↗ |
| 8-K | 2026-03-31 | 2026-03-31 | 0001193125-26-134501 ↗ |
| 8-K | 2026-03-23 | 2026-03-17 | 0001193125-26-119698 ↗ |
| 8-K | 2026-03-02 | 2026-02-24 | 0001539497-26-000812 ↗ |
| 8-K | 2026-02-09 | 2026-02-08 | 0001193125-26-041852 ↗ |
| 8-K | 2026-02-06 | 2026-02-06 | 0001193125-26-041367 ↗ |
| 8-K | 2026-01-30 | 2026-01-26 | 0001193125-26-031942 ↗ |
| 8-K | 2026-01-12 | 2026-01-09 | 0001193125-26-010458 ↗ |
| 8-K | 2025-12-31 | 2025-12-30 | 0001193125-25-337646 ↗ |